Matthew E. Ros Was Appointed Chief Operating Officer at Verastem Oncology
Career Updates
Matthew E. Ros Was Appointed Chief Operating Officer at Verastem Oncology
Verastem Oncology recently named Matthew E. Ros as its Chief Operating Officer.
About the Role
Matthew Ros is an executive with over 25 years of leadership experience in the biopharmaceutical and oncology sectors. He currently serves as the Chief Operating Officer at Verastem Oncology, where he drives the company’s strategic and operational initiatives. Matthew’s expertise spans corporate strategy, clinical development, business development, finance, and operational management.
Responsibilities
- Drive the company’s strategic and operational initiatives
- Lead the stabilization and advancement of clinical development of plixorafenib
- Secure $75 million in Series D financing
- Advance the development of TAZVERIK®
- Execute strategic collaborations with HUTCHMED and Quest Diagnostics
- Oversee restructuring of the oncology division
- Build a commercial infrastructure for TAZVERIK®
- Manage a $1.4 billion oncology franchise
Requirements
Matthew’s broad experience in oncology, combined with his leadership skills, has enabled him to guide organizations through complex clinical and commercial challenges, ultimately bringing new and innovative therapies to market.
Qualifications
- Executive with over 25 years of leadership experience in the biopharmaceutical and oncology sectors
- Expertise in corporate strategy, clinical development, business development, finance, and operational management
- Successful experience in stabilizing and advancing clinical development of oncology drugs
- Experience in raising substantial funding and executing strategic collaborations
- Leadership in restructuring and managing large-scale oncology franchises
- Proven track record in bringing innovative therapies to market
Skills
- Strategic planning and execution
- Financial management and budgeting
- Operational management and efficiency improvement
- Collaboration and partnership building
- Market analysis and competitive positioning
- Regulatory compliance and clinical trial oversight
Benefits
Matthew’s appointment as Chief Operating Officer at Verastem Oncology offers numerous benefits, including:
- Opportunities to lead and shape the future of oncology treatments
- Access to cutting-edge research and development in the field
- Challenges that require innovative solutions and strategic thinking
- Collaborative environment with experienced professionals
- Opportunities for professional growth and development
Pay
The exact compensation details are not specified in the provided information.
Schedule
The exact work schedule is not specified in the provided information.
Benefits
The exact benefits package is not specified in the provided information.